For anyone in Cefa searching for CJC-1295, the key fact to understand is that this compound moves through online research channels. The key implication for Cefa researchers: sourcing CJC-1295 depends entirely on vendor quality evaluation, not geography — and the evaluation methodology is the same regardless of where you are. A legitimate CJC-1295 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all traceable to your specific batch. This guide takes Cefa researchers through that evaluation process and explains how to verify CJC-1295 vendor quality step by step.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Cefa studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source CJC-1295 — Vendor Guide
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor make batch-matched COAs available before purchase? Those who make this data freely available are operating transparently. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. Warning signs in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, vague sourcing information, no community presence, and COAs that omit endotoxin testing. Price is an ineffective primary criterion for CJC-1295 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so significantly below-market pricing signals compromises.
Order CJC-1295 — ships to Cefa
COA-verified · International tracking · Research grade
CJC-1295 operates outside the framework of pharmaceutical oversight — researchers should understand that the safety data available for CJC-1295 is based on academic studies rather than pharmaceutical approval data. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution refrigerated at 2-8°C and used within 30 days; reconstitute only with bacteriostatic water. Endotoxin testing in the CJC-1295 COA is absolutely required — gram-negative bacterial endotoxins can trigger severe inflammatory responses at minute levels, and no pricing advantage justifies skipping this verification. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not a licensed human medication and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
